A new study suggests that low-cost generic statins are cost-effective for primary prevention of cardiovascular disease in high-risk but not in low-risk subgroups of patients with mild-to-moderate chronic kidney disease (CKD). The cost-effectiveness of statins is markedly reduced in patients with progressive CKD and in those at high-risk of drug-related adverse events.
This is a preview of subscription content, log in via an institution to check access.
References
United States Renal Data System. 2012 USRDS Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. United States Renal Data System [online], (2012).
Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 (2010).
Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807–814 (2012).
Lazar, L. D., Pletcher, M. J., Coxson, P. G., Bibbins-Domingo, K. & Goldman, L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124, 146–153 (2011).
Erickson, K. F. et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J. Am. Coll. Cardiol. 61, 1250–1258 (2013).
Grosse, S. D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8, 165–178 (2008).
Husereau, D. et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 346, f1049 (2013).
Nord, E., Pinto, J. L., Richardson, J., Menzel, P. & Ubel, P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 8, 25–39 (1999).
Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet (in press).
Oliver, A. Accounting for the missing opportunity costs in incremental cost-outcome analysis. Appl. Health Econ. Health Policy 1, 191–196 (2002).
Acknowledgements
V. Jha has received grant support from the Department of Biotechnology, Ministry of Science and Technology, Government of India and the Indian Council of Medical Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Jha, V., Modi, G. The price of a QALY—cost-effectiveness of statins in CKD. Nat Rev Nephrol 9, 377–379 (2013). https://doi.org/10.1038/nrneph.2013.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.104
- Springer Nature Limited
This article is cited by
-
Epidemiology of dyslipidemia in chronic kidney disease
Clinical and Experimental Nephrology (2014)